Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 561-568

  Sehn, Laurie H ^a   Alyea, Edwin P ^a   Weller, Edie ^a   Canning, Christine ^a   Lee, Stephanie ^a   Ritz, Jerome ^a   Antin, Joseph H ^a   Soiffer, Robert J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033015210     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.561     Document Type: Article

References (48)

1. Hale G, Cobbold S, Waldmann H: T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 45:753-759, 1988
2. Wagner JE, Santos GW, Noga SJ, et al: Bone marrow graft engineering by counterflow centrifugal elutriation: Results of a phase I-II clinical trial. Blood 75:1370-1377, 1990
3. Young JW, Papadopoulos EB, Cunningham I, et al: T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 79:3380-3387, 1992
4. Filipovich AH, Vallera D, McGlave P, et al: T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation: The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation 50:410-415, 1990
5. Antin JH, Bierer BE, Smith BR, et al: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139-2149, 1991
6. Soiffer RJ, Murray C, Mauch P, et al: Prevention of graft-versus-host disease by selective depletion of CD6 positive T lymphocytes from donor bone marrow. J Clin Oncol 10:1191-1200, 1992
7. Marmont AM, Horowitz MM, Gale RP, et al: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130, 1991
8. Goldman JM, Gale RP, Horowitz MM, et al: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806-814, 1988
9. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
10. Collins RH Jr, Shpilberg O, Drobyski WR, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997
11. Porter DL, Antin JH: Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am 12:123-150, 1998
12. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268, 1995
13. Giralt S, Hester J, Huh Y, et al: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337-4343, 1995
14. Alyea EP, Soiffer RJ, Canning C, et al: Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671-3680, 1998
15. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195-2204, 1996
16. Rohatiner A, Gelber R, Schlossman SF, et al: Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement: A quantitative and functional analysis. Transplantation 42:73-80, 1986
17. Przepiorka D, Weisdorf D, Martin P, et al: Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828, 1995
18. Armitage P, Berry G: Statistical Methods in Medical Research. Oxford, UK, Oxford University Press, 1987
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc 53:457-466, 1958
20. Craddock C, Szydlo R, Olavarria E, et al: Leukemia free survival after allogeneic transplantation for chronic myeloid leukemia: Effect of reclassifying responders to donor lymphocyte infusion as "currently free of leukemia." Blood 90:378b, 1997 (suppl) (abstr)
21. Korngold R, Leighton C, Manser T: Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58:278-287, 1994
22. Zutter MM, Martin PJ, Sale GE, et al: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520-529, 1988
23. Korngold R, Sprent J: T cell subsets and graft-versus-host disease. Transplantation 44:335-339, 1987
24. Okunewick JP, Kociban DL, Machen LL, et al: The role of CD4 and CD8 T-cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone Marrow Transplant 8:445-452, 1991
25. Kernan NA, Collins NH, Juliano L, et al: Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-vs-host disease. Blood 68:770-773, 1986
26. +T cells to graft-vs-host disease and graft-vs-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8:51-58, 1991
27. Theobald M, Nierle T, Bunjes D, et al: Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 327:1613-1617, 1992
28. Bunjes D, Theobald M, Hertenstein B, et al: Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin-2 secreting T helper cells. Bone Marrow Transplant 15:713-719, 1995
29. Nimer SD, Giorgi J, Gajewski JL, et al: Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: A randomized controlled trial. Transplantation 57:82-87, 1994
30. Soiffer RJ, Fairclough D, Robertson M, et al: CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 89:3039-3047, 1997
31. + T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 21:1177-1181, 1998
32. Porter DL, Collins R, Drobyski W, et al: Long term follow-up of 55 patients who achieved complete remission after donor leukocyte infusions for relapse after allogeneic bone marrow transplantation. Blood 90:549a, 1997 (suppl) (abstr)
33. Krenger W, Hill GR, Ferrara JLM: Cytokine cascades in acute graft-versus-host disease. Transplantation 64:553-558, 1997
34. Holler E, Kolb HJ, Mittermueller J, et al: Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86:890-899, 1995
35. Nestel FP, Price KS, Seemayer TA, et al: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405-413, 1992
36. Xun CQ, Thompson JS, Jennings CD, et al: Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360-2367, 1994
37. Johnson BD, Truitt RL: Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85:3302-3312, 1995
38. Johnson B, Drobyski W, Truitt R: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329-336, 1993
39. Sullivan KM, Storb R, Buckner CD, et al: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828-834, 1989
40. Barrett AJ, Mavroudis D, Tisdale J, et al: T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21:543-551, 1998
41. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response? Bone Marrow Transplant 15:591-594, 1995
42. Drobyski WR, Keever CA, Roth MS, et al: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310-2318, 1993
43. van Rhee F, Lin F, Cullis JO, et al: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-3383, 1994
44. Naparstek E, Or R, Nagler A, et al: T-cell depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506-515, 1995
45. Pichert G, Alyea EP, Soiffer RJ, et al: Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood 84:2109-2114, 1994
46. Miyamura K, Barrett A, Kodera Y, et al: Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: A review of recent results. Bone Marrow Transplant 14:201-209, 1994
47. Antin JH, Weinstein HJ, Guinan EC, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84:1342-1348, 1994
48. McCarthy PL, Abhyankar S, Neben S, et al: Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915-1918, 1991